Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Hospital Universitario Ramon y Cajal, Madrid, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:4City/State/Province:Madrid
Treatments:ChemotherapyHospital:Hospital Universitario Ramon y Cajal
Drugs:Journal:Link
Date:May 2005

Description:

Patients: This Phase II study involved 78 women with recurrent platinum-sensitive ovarian cancer. The patients were randomized into two groups. The median age for Group A (40 women) was 61. All Group A patients had received one or two chemotherapy treatments prior to the study.

Treatment: Patients in Group A received one chemotherapeutic agent: carboplatin.

Toxicity: In Group A, grade 3-4 toxicities included neutropenia, anemia, thrombocytopenia, and vomiting.

Results: The median overall survival for Group A was reported at 16.8 months.

Support: Bristol Meyers Squibb provided financial support for this study. Bristol Meyers Squibb manufactures and markets both carboplatin and paclitaxel.

Correspondence: Dr. A. J. Gonzalez Martin





Back